Clinical Trials

54 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07044544 2026-03-04

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT07283094 2026-03-03

FHD-286

33 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06511882 2026-02-27

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

37 enrolled

Leukemia, Myeloid, Acute

NCT01515527 2026-02-06

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

160 enrolled

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03661307 2026-01-12

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Phase 1/2 Recruiting

73 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05184842 2026-01-05

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

91 enrolled 26 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06928662 2025-11-06

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Phase 1/2 Recruiting

36 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06429098 2025-09-04

Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML

40 enrolled

Leukemia, Myeloid, Acute

NCT06129734 2025-08-26

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Phase 1/2 Recruiting

Leukemia, Myeloid, Acute

NCT05829226 2025-05-28

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

90 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT05586074 2025-04-09

HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

Phase 3 Recruiting

324 enrolled

Leukemia, Myeloid, Acute

NCT05190471 2025-03-10

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

48 enrolled

Leukemia, Myeloid, Acute

NCT02781883 2025-03-07

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

108 enrolled

Leukemia, Myeloid, Acute

NCT06741722 2024-12-27

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML

Leukemia, Myeloid, Acute

NCT06316960 2024-08-22

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

50 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT06536959 2024-08-05

VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

67 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04905810 2024-05-29

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

Leukemia, Myeloid, Acute

NCT06046313 2024-03-05

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS

120 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03793517 2020-03-10

Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT

Phase 2/3 Recruiting

55 enrolled